Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 15/20 | 1.00 |
| ▸ | DDO | Q99489 | 5/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30077634 | 1.00 | DAO (1.00) | DAODDOBRD4CHEK1KDR | |
| SCHEMBL3237176 | 0.98 | DAO (0.96) | DAODDOBRD4CHEK1KDR | |
| Sulfuric Acid SCHEMBL1467316 | 0.93 | DAO (0.86) | DAODDOBRD4CHEK1KDR | |
| SCHEMBL8873240 | 0.88 | DAO (0.79) | DAODDOBRD4CHEK1KDR | |
| SCHEMBL17175695 | 0.78 | DAO (0.64) | DAODDOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL2639080 | 0.76 | DAO (0.61) | DAODDOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL1367711 | 0.76 | DAO (0.61) | DAODDOBRD4CHEK1KDR | |
| SCHEMBL7341095 | 0.76 | DAO (0.61) | DAODDOGRIN2DGRIN3BGRIN1 | |
| SCHEMBL1625559 | 0.75 | DAO (0.60) | DAODDOBRD4CHEK1KDR | |
| SCHEMBL545302 | 0.75 | DAO (0.60) | DAODDOBRD4CHEK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504712-A1 | GPR35 MODULATORS AND USES THEREOF | Crossignal Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| CN-119137105-A | GPR35 modulators and uses thereof | 交信医药研发公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118680838-A | Freckle-removing and whitening compound and preparation method thereof | 广州颜当家化妆品科技有限公司 | 2024-09-24 | — | — | CN | claimed |
| WO-2023196538-A1 | GPR35 MODULATORS AND USES THEREOF | CROSSIGNAL THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | claimed |
| EP-3071634-B1 | SELF-HEALING POLYMERIC COMPOSITION | BATTELLE MEMORIAL INSTITUTE (US) | 2023-08-30 | — | — | EP | claimed |
| CN-116589403-A | 3-hydroxyquinoline-2-ketone compound and synthetic method and application thereof | 浙江工业大学 | 2023-08-15 | — | — | CN | claimed |
| EP-2802871-B1 | CHARACTERIZATION OF SUBVISIBLE PARTICLES USING A PARTICLE ANALYZER | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-27 | — | — | EP | claimed |
| US-10752606-B2 | Methods for treating protozoan infections | NEOCULI PTY LTD. (AU) | 2020-08-25 | — | — | US | claimed |
| US-20200102287-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2020-04-02 | — | — | US | claimed |
| US-10562880-B2 | Methods for treating protozoan infections | NEOCULI PTY LTD. (AU) | 2020-02-18 | — | — | US | claimed |
| WO-2009064291-A1 | CYANOACRYLATE TISSUE ADHESIVES | SPARTAN MEDICAL PRODUCTS, LLC (US) | 2009-05-22 | — | — | WO | claimed |
| EP-1509236-A4 | TREATMENT AND PREVENTION OF ABNORMAL SCAR FORMATION IN KELOIDS AND OTHER CUTANEOUS OR INTERNAL WOUNDS OR LESIONS | CHILDREN S HOSPITAL LOS ANGELE (US) | 2008-07-30 | — | — | EP | claimed |
| US-20070281360-A1 | PROTEIN DETECTION AND QUANTITATION USING HYDROXYQUINOLONE DYES | PIERCE BIOTECHNOLOGY, INC. (US) | 2007-12-06 | — | — | US | claimed |
| EP-1509236-A2 | TREATMENT AND PREVENTION OF ABNORMAL SCAR FORMATION IN KELOIDS AND OTHER CUTANEOUS OR INTERNAL WOUNDS OR LESIONS | Children's Hospital of Los Angeles (US) | 2005-03-02 | — | — | EP | claimed |
| WO-2004041155-A2 | TREATMENT AND PREVENTION OF ABNORMAL SCAR FORMATION IN KELOIDS AND OTHER CUTANEOUS OR INTERNAL WOUNDS OR LESIONS | CHILDREN'S HOSPITAL LOS ANGELES (US) | 2004-05-21 | — | — | WO | claimed |
| US-20040043026-A1 | Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-04 | — | — | US | claimed |
| US-20030162951-A1 | Yellow disperse dye mixture | DYSTAR TEXTILFARBEN GMBH & CO. DEUTSCHLAND KG (DE) | 2003-08-28 | — | — | US | claimed |
| EP-0752452-B1 | Hydroxyquinolone-monoazo dyes, their preparation and use | DYSTAR TEXTILFARBEN GMBH & CO (DE) | 2001-09-12 | — | — | EP | claimed |
| WO-2001047481-A1 | COMPOSITION FOR THE TREATMENT OF DANDRUFF | PHARMASKIN LTD. (IL) | 2001-07-05 | — | — | WO | claimed |
| US-5760197-A | YELLOW PIGMENT FOR DYEING TEXTILES | DYSTAR JAPAN LTD. (JP) | 1998-06-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102287-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | DAO 995/4885DDO 1823/4885BRD4 4083/4885 |
| US-10562880-B2 | Methods for treating protozoan infections | DPM1, ABCB11, PIGS | DAO 995/4885DDO 1823/4885BRD4 4083/4885 |
| US-10752606-B2 | Methods for treating protozoan infections | DPM1, ABCB11, PIGS | DAO 995/4885DDO 1823/4885BRD4 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.